Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19

- New data show therapy reduced risk of hospitalizations and death by 87 percent - Second positive Phase 3 trial readout for bamlanivimab and etesevimab together - Results support use of bamlanivimab 700 mg and etesevimab 1400 mg, the dose authorized in U.S.